DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLORBETAPIR F-18

Clinical Trials for Florbetapir F-18

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00702143	A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)	Completed	Avid Radiopharmaceuticals	Phase 2	Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
NCT00857415	Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain	Completed	Avid Radiopharmaceuticals	Phase 3	The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
NCT00857506	Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)	Completed	Avid Radiopharmaceuticals	Phase 2	The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 months for groups of: normal controls, mild cognitive impairment and Alzheimer's disease. Hypothesis 1: The probability a subject will experience progressive cognitive impairment within 36 months of imaging will be greater in subjects whose 18F-AV-45 PET scan was rated amyloid positive compared to subjects whose PET scan was rated amyloid negative. The secondary objective is to determine the stability, over 36 months of a clinical diagnosis, of AD in patients with an amyloid positive 18F-AV-45 PET. Hypothesis 2: The diagnosis of AD will remain unchanged in patients whose PET scan were rated as amyloid positive.
NCT00857532	Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT00857532	Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients	Completed	National Institutes of Health (NIH)	Phase 2	The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT00857532	Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients	Completed	Avid Radiopharmaceuticals	Phase 2	The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
Trial ID	Title	Status	Sponsor	Phase	Summary